Biondvax Pharmaceuticals BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) was founded in 2003 and is headquartered in Ness Ziona, Israel, with 15 full-time employees. It is a clinical-stage biopharmaceutical company focusing on the development and commercialization of immunomodulatory therapies for infectious diseases in Israel .
BiondVax Pharmaceuticals Ltd. (BVXV):
BiondVax Pharmaceuticals is committed to developing a new universal flu vaccine. BiondVax’s universal flu vaccine is based on more than two decades of research by Professor Ruth Arnon of the Weizmann Institute of Science, who is the head of the company’s scientific advisory board. Professor Arnon is famous for developing Copaxone®, a blockbuster drug used to treat multiple sclerosis.
BiondVax’s technology utilizes a unique and proprietary combination of conserved and common epitopes from influenza virus proteins to activate the two arms of the immune system to achieve cross-protection and lasting effects. The company holds an exclusive global license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, for the development, production and commercialization of this innovative influenza vaccine.
BiondVax Pharmaceuticals’ product candidate is M-001, a synthetic peptide-based protein that has completed phase II clinical trials for the treatment of seasonal and pandemic strains of influenza virus. M-001 has successfully completed 6 human clinical trials. A phase II trial sponsored by the National Institutes of Health is underway in the United States, and a pivotal phase III trial for clinical efficacy began in 2018.
The 15-person team of BiondVax includes scientists, technicians, researchers and administrative staff. The company has the most advanced GMP facilities in Israel, including its laboratories, production facilities and offices.